Join the 'Idiopathic (Immune) Thrombocytopenic Purpura' group to help and get support from people like you.
Idiopathic (Immune) Thrombocytopenic Purpura News
Related terms: Immune Thrombocytopenic Purpura, ITP
FDA Extends Use of Promacta (eltrombopag) in Pediatric Patients with Immune Thrombocytopenic Purpura
Posted 24 Aug 2015 by Drugs.com
August 24, 2015 – The U.S. Food and Drug Administration today approved Promacta (eltrombopag) to treat low blood platelet count in pediatric patients – ages one year and older – with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). Promacta can be used in these children when they have not achieved an appropriate response using other ITP medicines or surgery to remove th ...
Posted 24 Aug 2015 by Drugs.com
MONDAY, Aug. 24, 2015 – U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children one year and older with a rare blood disorder called chronic immune thrombocytopenic purpura (ITP). ITP is characterized by a low blood platelet count. Promacta is now approved for the disorder among children who have had unsatisfactory results with other ...
Posted 14 Jun 2015 by Drugs.com
SAN DIEGO, June 12, 2015 --(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the FDA has approved a supplemental New Drug Application (sNDA) for the use of Promacta (eltrombopag), a Novartis product, for the treatment of children six years and older with chronic immune thrombocytopenia (cITP) who have had an insufficient response to corticosteroids, ...
Posted 24 Nov 2008 by Drugs.com
MONDAY, Nov. 24 – The U.S. Food and Drug Administration has approved Promacta (eltrombopag) to treat a rare condition in which the body attacks its own blood platelets. Chronic immune thrombocytopenic purpura (ITP) affects about 60,000 people in the United States, according to a news release from the drug's maker, GlaxoSmithKline. ITP patients often bleed from small blood vessels, resulting in ...
Posted 22 Aug 2008 by Drugs.com
FRIDAY, Aug. 22 – The U.S. Food and Drug Administration has approved Nplate (romiplostim), a drug that stimulates bone marrow to make needed platelets in people with a rare bleeding disorder called immune thrombocytopenic purpura (ITP). The disorder, affecting about 140,000 people in the United States, causes a low count of platelets, a component that helps blood clot. In people with chronic ...
Ask a Question
Related Condition Support Groups
Related Drug Support Groups
prednisone, cortisone, triamcinolone, dexamethasone, cyclosporine, rituximab, Decadron, azathioprine, Kenalog-40, view more... Neoral, RhoGAM, Nplate, Gammagard, interferon alfa-2b, Gamunex, Deltasone, Privigen, Carimune, immune globulin intravenous, Gamunex-C, Promacta, Intron A, romiplostim, WinRho SDF, Carimune NF, Liquid Pred, rho (d) immune globulin, Rhophylac, eltrombopag, Adrenocot LA, Dexone, Sandoglobulin, Sandimmune, Adrenocot, Gengraf, Octagam, Sterapred, Sterapred DS, D-Gam Anti-D, BayRHo-D Mini-Dose, Partobulin SDF, BayRHo-D Full Dose, Liberim D, BayRHo-D, HypRho-D Mini-Dose, Mini-Gamulin Rh, Gamulin Rh, HyperRHO S / D Full Dose, Gamimune, HyperRHO S / D Mini-Dose, Dexamethasone Intensol, Baycadron, Dalalone, Dalalone DP, Zonacort, Decaject, Decaject LA, Gammaplex, Gammar IV, Zema Pak, Gammaked, Dalalone LA, Prednicot, Iveegam En, Primethasone, immune globulin intravenous and subcutaneous, Flebogamma, Panglobulin NF, MICRhoGAM, Hexadrol, Decadron-LA, Solurex LA, Dexacen-4, Solurex, De-Sone LA, Dexacort-LA, Dexasone, Dexasone LA, Dexone LA, Dexacorten, Panglobulin, Gammagard S / D, Gamimune N 10%, Gamimune N 5%, Polygam S / D, Gammar-P IV, Venoglobulin-S 10%, Venoglobulin-S 5%, Clinacort, Medidex, Cortone Acetate, Prednicen-M, Orasone, Meticorten, Dexpak Taperpak, Medidex LA, LoCort